AU2019229334A1 — Substituted heterocycle fused gamma-carbolines synthesis
Assigned to Intra Cellular Therapies Inc · Expires 2019-10-03 · 7y expired
What this patent protects
A pharmaceutical composition comprising toluenesulfonic acid and the compound of Formula 2J: R9 k N R5 R8H R*) (S* )M R6 a R6 b 5 Formula 2J or a pharmaceutically acceptable salt thereof, wherein: (i) k is 1; (ii) m is 1; (iii) n is 1; 10 (iv) RI is 4-(4-fluorophenyl)-4-oxobutyl;…
USPTO Abstract
A pharmaceutical composition comprising toluenesulfonic acid and the compound of Formula 2J: R9 k N R5 R8H R*) (S* )M R6 a R6 b 5 Formula 2J or a pharmaceutically acceptable salt thereof, wherein: (i) k is 1; (ii) m is 1; (iii) n is 1; 10 (iv) RI is 4-(4-fluorophenyl)-4-oxobutyl; (v) R is H; (vi) R6a and R 6 are independently H; (vii) R', R8 and R9 are independently H; (viii) R10 is CH3; and 15 (ix) X is -N-.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.